{"organizations": [], "uuid": "292d7f0b8c2f04207128bdfa82ba5f28bcb256ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-inventiva-says-lanifibranor-carcin/brief-inventiva-says-lanifibranor-carcinogenicity-studies-are-progressing-as-planned-idUSFWN1RA0V1", "country": "US", "domain_rank": 408, "title": "BRIEF-Inventiva Says Lanifibranor Carcinogenicity Studies Are Progressing As Planned", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.212, "site_type": "news", "published": "2018-03-29T00:21:00.000+03:00", "replies_count": 0, "uuid": "292d7f0b8c2f04207128bdfa82ba5f28bcb256ed"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-inventiva-says-lanifibranor-carcin/brief-inventiva-says-lanifibranor-carcinogenicity-studies-are-progressing-as-planned-idUSFWN1RA0V1", "ord_in_thread": 0, "title": "BRIEF-Inventiva Says Lanifibranor Carcinogenicity Studies Are Progressing As Planned", "locations": [], "entities": {"persons": [{"name": "inventiva", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - INVENTIVA SA:\n* LANIFIBRANOR CARCINOGENICITY STUDIES: PROGRESSING AS PLANNED\n* LANIFIBRANOR CARCINOGENICITY STUDIES: INTERIM RESULTS IN RATS INDICATE NO COMPOUND RELATED URINARY BLADDER TUMORS\n* 104-WEEK IN-LIFE PERIOD COMPLETED\n* FINAL PEER-REVIEWED RESULTS EXPECTED FOR BOTH SPECIES BY END OF Q2 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T00:21:00.000+03:00", "crawled": "2018-03-29T16:14:40.005+03:00", "highlightTitle": ""}